drugset / Trial / NCT00185874

Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases

NCT00185874

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Up to twenty-two patients will be enrolled in this study to receive autologous dendritic cells (DCs) administered intratumorally into liver metastases following radiofrequency thermal ablation of those lesions. Patients will receive two vaccinations of DCs at monthly intervals. A dose escalation study of DCs will be included in this study in an attempt to define the maximum tolerated dose of administered DCs.

Timeline

Start
2004-01
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous dendritic cells Cell therapy Other

Indications